Canopy Growth, Aphria, or Aurora Cannabis: Which Canadian Marijuana Stock Will Be on Top?

Share on Linkedin

Since March 24, Aphria Inc. (TSE:APH) has surged more than 35%, Aurora Cannabis Inc. (CVE:ACB) has soared about 44% while Canopy Growth Corp. (TSE:WEED) has risen 10%

Motley Fool Canada | April 13, 2017: Aphria Inc. (TSX: APH) has been soaring since its graduation to the TSX last month. The company now has a $1.1 billion market cap and could pass Canopy Growth Corp. (TSX: WEED) with its $1.74 billion market cap over the next few months.

There’s no question Canopy stock has slowed down when compared to its peers such as Aphria and Aurora Cannabis Inc. (TSXV: ACB). Canopy is up approximately 10% since March 24, the date when Aphria moved to the TSX, while Aphria is up a whopping 35.3%, and Aurora Cannabis is up an astounding 44.3% over the same span.

Related: Find The Best Canadian Marijuana Stocks or Pot Stock to Invest In

In many of my previous pieces this year, I recommended Aurora Cannabis and Aphria over Canopy because of fundamental reasons and the scandal which suppressed the current upward rally being enjoyed by all marijuana stocks.

Don’t get me wrong. Obtaining a 10% return in less than a month is still extraordinary! But let’s not forget that Canopy got beaten up pretty badly following the class-action lawsuit that resulted from the tainted marijuana scandal, and the stock still hasn’t fully rebounded from the correction that followed.

Win Big With Our Small Cap Picks

 

Sure, all marijuana stocks pulled back slightly, but it looks like investors have decided what their new favourite pot stock is. Over the short and medium term, I believe Canopy won’t get as high as Aurora or Aphria. Both of these companies are firing on all cylinders and are very likely to give Canopy a run for its money.

Back in the day, Canopy was one of the only go-to pot stock for investors. It was the first to graduate to the TSX, and marijuana investors poured money in. But now we’re likely to see more pot stocks suddenly popping up on the TSX, and there’s even a marijuana ETF for those who want a small piece of all marijuana stocks.

There are more options for investors these days, and it’s likely that original Canopy investors will jump ship to more interesting opportunities. The tainted marijuana scandal most likely accelerated this phenomenon.

I still think Aphria and Aurora are better bets over the medium term, but Canopy is likely to get out of its funk and start soaring with a similar magnitude as these two pot powerhouses.

Although any investment in marijuana is risky, I think an investment in Canopy ups the amount of risk without raising the upside potential thanks to the scandal, which may result in more negative news down the road. Eventually, Canopy will become a “value” play in the marijuana industry, and by then, it’s likely that the magnitude of its returns will be more in line with those of its peers.

Read more at fool.ca

[Editor’s Note: Aurora Cannabis announced recently that it will increase the size of its previously announced bought deal private placement of convertible debentures to C$75 million. Aurora Cannabis added that net proceeds from the Offering will be used primarily towards international expansion and growth opportunities. “This lower cost financing places Aurora in an extremely powerful position to aggressively pursue international expansion opportunities, with what we believe will be the strongest cash balance, at more than $150 million, in the global cannabis sector,” said Terry Booth, CEO of Aurora Cannabis. “With our existing facility in Mountain View County, Alberta, construction proceeding rapidly on Aurora Sky at the Edmonton International Airport, and the recent acquisition of Peloton Pharmaceuticals in Quebec, we are also developing what we expect will be the largest cannabis production capacity in the world, grown to the Aurora Standard. Combined with our technological innovation, one-of-a-kind mobile application and e-commerce strategy, Aurora is ideally placed to play a leading role not only in the Canadian medical and consumer cannabis markets, but also in multiple emerging global cannabis markets.”]

Disclosure: Neither any of the principals at Small Cap Power, nor their family members, own shares in any of the companies mentioned above.

The Content contained on this page (including any facts, views, opinions, recommendations, description of, or references to, products or securities) made available by SmallCapPower/Ubika Research is for information purposes only and is not tailored to the needs or circumstances of any particular person. Any mention of a particular security is merely a general discussion of the merits and risks associated there with and is not to be used or construed as an offer to sell, a solicitation of an offer to buy, or an endorsement, recommendation, or sponsorship of any entity or security by SmallCapPower/Ubika Research. To read more of this Disclaimer please click on the button below: